This segment focuses on the research, development, and commercialization of the RapiDerm skin drug delivery system for dermatological diseases. R&D activities include formulation development, preclinical studies, and clinical trials to assess efficacy and safety. The technology utilizes innovative methods to enhance drug penetration and improve therapeutic outcomes for various skin conditions. The therapeutic areas covered include, but are not limited to, eczema, psoriasis, and other inflammatory skin diseases. The patient impact is significant, as RapiDerm aims to provide more effective and convenient treatments, improving patient quality of life. Suvanza's market positioning is as an early-stage biotechnology company with a focus on innovative drug delivery. Future opportunities include expanding the product pipeline and securing partnerships for commercialization. Regulatory and clinical aspects involve obtaining FDA approval and conducting clinical trials to demonstrate safety and efficacy. This segment is actively seeking collaborations with pharmaceutical companies and dermatologists to advance its product development and market reach.